Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PBLA |
---|---|---|
10:11 ET | 100 | 0.333 |
02:02 ET | 1500 | 0.3576 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Panbela Therapeutics Inc | 1.7M | 0.0x | --- |
Dermata Therapeutics Inc | 1.7M | -0.1x | --- |
Kiromic Biopharma Inc | 1.7M | -0.1x | --- |
Allarity Therapeutics Inc | 1.8M | 0.0x | --- |
Biostax Corp | 1.9M | -1.2x | --- |
Bluejay Diagnostics Inc | 1.9M | 0.0x | --- |
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.9M |
Panbela Therapeutics Inc does not pay a dividend. | |
Beta | 0.98 |
EPS | $-31.75 |
Book Value | $-9.81 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.